(Reuters) – Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.
Data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a “clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks”, the Swiss drugmaker said in a statement
The drug “was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class”, the statement added.
(Reporting by Paolo Laudani, Editing by Rachel More)
Comments